当前位置： SCI文献检索 > CANCER CELL期刊下所有文献 > CHAF1B Overexpression: A Brake for the Differentiation of Leukemia Cells.

CHAF1B Overexpression: A Brake for the Differentiation of Leukemia Cells.

Abstract：

:In this issue of Cancer Cell, Volk et al. report that overexpression of CHAF1B displaces myeloid transcription factors from chromatin, and deletion of CHAF1B promotes differentiation of leukemia cells and suppresses leukemogenesis in a murine model, revealing a causal role of and an unexpected mechanism for CHAF1B overexpression in tumorigenesis.

journal_name

Cancer Cell

journal_title

Cancer cell

authors

Li Q,Zhang X,Zhang Z

doi

10.1016/j.ccell.2018.10.011

subject

Has Abstract

pub_date

2018-11-12 00:00:00

pages

693-694

issue

5

eissn

1535-6108

issn

1878-3686

pii

S1535-6108(18)30477-X

journal_volume

34

pub_type

评论,杂志文章

相关文献

CANCER CELL文献大全
  • Leaving home early: reexamination of the canonical models of tumor progression.

    abstract：:A recent report in Science from the Varmus laboratory (Podsypanina et al., 2008) puts an interesting twist on the origins of metastatic cells, suggesting that metastases can arise in ways that are very different from those widely believed. ...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2008.09.009

    authors： Weinberg RA

    更新日期：2008-10-07 00:00:00

  • The HECT family of E3 ubiquitin ligases: multiple players in cancer development.

    abstract：:The involvement of the homologous to E6-AP carboxyl terminus (HECT)-type E3s in crucial signaling pathways implicated in tumorigenesis is presently an area of intense research and extensive scientific interest. This review highlights recent discoveries on the ubiquitin-mediated degradation of crucial tumor suppressor ...

    journal_title：Cancer cell

    pub_type： 杂志文章,评审

    doi：10.1016/j.ccr.2008.06.001

    authors： Bernassola F,Karin M,Ciechanover A,Melino G

    更新日期：2008-07-08 00:00:00

  • Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors.

    abstract：:Neuroendocrine (NE) phenotype, seen in >30% of prostate adenocarcinomas (PCa), and NE prostate tumors are implicated in aggressive prostate cancer. Formation of NE prostate tumors in the TRAMP mouse model was suppressed in mice lacking the ubiquitin ligase Siah2, which regulates HIF-1alpha availability. Cooperation be...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2010.05.024

    authors： Qi J,Nakayama K,Cardiff RD,Borowsky AD,Kaul K,Williams R,Krajewski S,Mercola D,Carpenter PM,Bowtell D,Ronai ZA

    更新日期：2010-07-13 00:00:00

  • Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation.

    abstract：:Somatic loss-of-function mutations in the ten-eleven translocation 2 (TET2) gene occur in a significant proportion of patients with myeloid malignancies. Although there are extensive genetic data implicating TET2 mutations in myeloid transformation, the consequences of Tet2 loss in hematopoietic development have not b...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2011.06.001

    authors： Moran-Crusio K,Reavie L,Shih A,Abdel-Wahab O,Ndiaye-Lobry D,Lobry C,Figueroa ME,Vasanthakumar A,Patel J,Zhao X,Perna F,Pandey S,Madzo J,Song C,Dai Q,He C,Ibrahim S,Beran M,Zavadil J,Nimer SD,Melnick A,Godley LA

    更新日期：2011-07-12 00:00:00

  • Nuclear factor-kappaB: the enemy within.

    abstract：:Numerous lines of investigation suggest that nuclear factor NF-kappaB, a proinflammatory transcription factor, could promote tumorigenesis. Various inflammatory agents, carcinogens, tumor promoters, and the tumor microenvironment activate NF-kappaB. NF-kappaB proteins themselves and proteins regulated by it have been ...

    journal_title：Cancer cell

    pub_type： 杂志文章,评审

    doi：10.1016/j.ccr.2004.09.003

    authors： Aggarwal BB

    更新日期：2004-09-01 00:00:00

  • Proapoptotic activation of death receptor 5 on tumor endothelial cells disrupts the vasculature and reduces tumor growth.

    abstract：:The proapoptotic death receptor DR5 has been studied extensively in cancer cells, but its action in the tumor microenvironment is not well defined. Here, we uncover a role for DR5 signaling in tumor endothelial cells (ECs). We detected DR5 expression in ECs within tumors but not normal tissues. Treatment of tumor-bear...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2012.05.014

    authors： Wilson NS,Yang A,Yang B,Couto S,Stern H,Gogineni A,Pitti R,Marsters S,Weimer RM,Singh M,Ashkenazi A

    更新日期：2012-07-10 00:00:00

  • Deubiquitination and Stabilization of PD-L1 by CSN5.

    abstract：:Pro-inflammatory cytokines produced in the tumor microenvironment lead to eradication of anti-tumor immunity and enhanced tumor cell survival. In the current study, we identified tumor necrosis factor alpha (TNF-α) as a major factor triggering cancer cell immunosuppression against T cell surveillance via stabilization...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2016.10.010

    authors： Lim SO,Li CW,Xia W,Cha JH,Chan LC,Wu Y,Chang SS,Lin WC,Hsu JM,Hsu YH,Kim T,Chang WC,Hsu JL,Yamaguchi H,Ding Q,Wang Y,Yang Y,Chen CH,Sahin AA,Yu D,Hortobagyi GN,Hung MC

    更新日期：2016-12-12 00:00:00

  • Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo.

    abstract：:There is currently much interest in the idea of restoring p53 activity in tumor cells by inhibiting Hdm2/Mdm2. However, it has remained unclear whether this would also activate p53 in normal cells. Using a switchable endogenous p53 mouse model, which allows rapid and reversible toggling of p53 status between wild-type...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2006.10.010

    authors： Ringshausen I,O'Shea CC,Finch AJ,Swigart LB,Evan GI

    更新日期：2006-12-01 00:00:00

  • Rac guanosine triphosphatases represent integrating molecular therapeutic targets for BCR-ABL-induced myeloproliferative disease.

    abstract：:Chronic myelogenous leukemia (CML) is a clonal myeloproliferative disease (MPD) initiated by expression of the p210-BCR-ABL fusion protein. We demonstrate in a murine model of p210-BCR-ABL-induced MPD that gene targeting of Rac1 and Rac2 significantly delays or abrogates disease development. Attenuation of the disease...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2007.10.015

    authors： Thomas EK,Cancelas JA,Chae HD,Cox AD,Keller PJ,Perrotti D,Neviani P,Druker BJ,Setchell KD,Zheng Y,Harris CE,Williams DA

    更新日期：2007-11-01 00:00:00

  • Optimal gene expression analysis by microarrays.

    abstract：:DNA microarrays make possible the rapid and comprehensive assessment of the transcriptional activity of a cell, and as such have proven valuable in assessing the molecular contributors to biological processes and in the classification of human cancers. The major challenge in using this technology is the analysis of it...

    journal_title：Cancer cell

    pub_type： 杂志文章,评审

    doi：10.1016/s1535-6108(02)00181-2

    authors： Miller LD,Long PM,Wong L,Mukherjee S,McShane LM,Liu ET

    更新日期：2002-11-01 00:00:00

  • BRAF inhibitor unveils its potential against advanced melanoma.

    abstract：:Unresponsiveness to therapy is a hallmark feature of advanced metastatic melanoma. However, the discovery of BRAF-activating mutations in approximately 50% of human melanomas has provided an attractive therapeutic target. Here, we discuss two recent publications focusing on the mutant BRAF kinase inhibitor PLX4032 tha...

    journal_title：Cancer cell

    pub_type： 评论,杂志文章

    doi：10.1016/j.ccr.2010.10.001

    authors： Vultur A,Villanueva J,Herlyn M

    更新日期：2010-10-19 00:00:00

  • No need for constant help: human IgG2 antibodies have an autonomous agonistic activity for immunotherapy of cancer.

    abstract：:Agonistic antibodies specific for members of the tumor necrosis factor receptor protein family hold great promise for immunotherapy of cancer. In this issue of Cancer Cell, White and colleagues provide evidence that the human IgG2 subclass may represent a superior backbone for the use of these antibodies in human ther...

    journal_title：Cancer cell

    pub_type： 评论,杂志文章

    doi：10.1016/j.ccell.2014.12.010

    authors： Lux A,Nimmerjahn F

    更新日期：2015-01-12 00:00:00

  • RalGDS is required for tumor formation in a model of skin carcinogenesis.

    abstract：:To investigate the role of signaling by the small GTPase Ral, we have generated mice deficient for RalGDS, a guanine nucleotide exchange factor that activates Ral. We show that RalGDS is dispensable for mouse development but plays a substantial role in Ras-induced oncogenesis. Lack of RalGDS results in reduced tumor i...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2005.01.029

    authors： González-García A,Pritchard CA,Paterson HF,Mavria G,Stamp G,Marshall CJ

    更新日期：2005-03-01 00:00:00

  • EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma.

    abstract：:EGFRvIII, a frequently occurring mutation in primary glioblastoma, results in a protein product that cannot bind ligand, but signals constitutively. Deducing how EGFRvIII causes transformation has been difficult because of autocrine and paracrine loops triggered by EGFRvIII alone or in heterodimers with wild-type EGFR...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2013.09.004

    authors： Fan QW,Cheng CK,Gustafson WC,Charron E,Zipper P,Wong RA,Chen J,Lau J,Knobbe-Thomsen C,Weller M,Jura N,Reifenberger G,Shokat KM,Weiss WA

    更新日期：2013-10-14 00:00:00

  • The risk-associated long noncoding RNA NBAT-1 controls neuroblastoma progression by regulating cell proliferation and neuronal differentiation.

    abstract：:Neuroblastoma is an embryonal tumor of the sympathetic nervous system and the most common extracranial tumor of childhood. By sequencing transcriptomes of low- and high-risk neuroblastomas, we detected differentially expressed annotated and nonannotated long noncoding RNAs (lncRNAs). We identified a lncRNA neuroblasto...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2014.09.014

    authors： Pandey GK,Mitra S,Subhash S,Hertwig F,Kanduri M,Mishra K,Fransson S,Ganeshram A,Mondal T,Bandaru S,Ostensson M,Akyürek LM,Abrahamsson J,Pfeifer S,Larsson E,Shi L,Peng Z,Fischer M,Martinsson T,Hedborg F,Kogner P,

    更新日期：2014-11-10 00:00:00

  • Crosstown Traffic: Lymphodepleting Chemotherapy Drives CAR T Cells.

    abstract：:CAR-engineered T cell immunotherapy has proven transformative in selected hematological malignancies. However, solid tumors largely remain impervious to these approaches. In addressing this challenge, Srivastava et al. in this issue demonstrate that oxaliplatin-based lymphodepleting chemotherapy promotes enhanced CAR ...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2020.12.019

    authors： Davies DM,Maher J

    更新日期：2020-12-30 00:00:00

  • PGC1α expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress.

    abstract：:Cancer cells reprogram their metabolism using different strategies to meet energy and anabolic demands to maintain growth and survival. Understanding the molecular and genetic determinants of these metabolic programs is critical to successfully exploit them for therapy. Here, we report that the oncogenic melanocyte li...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2012.11.020

    authors： Vazquez F,Lim JH,Chim H,Bhalla K,Girnun G,Pierce K,Clish CB,Granter SR,Widlund HR,Spiegelman BM,Puigserver P

    更新日期：2013-03-18 00:00:00

  • SnapShot: Immune Checkpoint Inhibitors.

    abstract：:Immunotherapy has changed the landscape of cancer treatment. Checkpoint blockade therapies unleash breaks in the immune system and induce long-lasting responses. However, a significant number of patients do not respond (innate resistance), and a subset progress after responding (acquired resistance). A better understa...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2017.05.010

    authors： Abril-Rodriguez G,Ribas A

    更新日期：2017-06-12 00:00:00

  • p62, Upregulated during Preneoplasia, Induces Hepatocellular Carcinogenesis by Maintaining Survival of Stressed HCC-Initiating Cells.

    abstract：:p62 is a ubiquitin-binding autophagy receptor and signaling protein that accumulates in premalignant liver diseases and most hepatocellular carcinomas (HCCs). Although p62 was proposed to participate in the formation of benign adenomas in autophagy-deficient livers, its role in HCC initiation was not explored. Here we...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2016.04.006

    authors： Umemura A,He F,Taniguchi K,Nakagawa H,Yamachika S,Font-Burgada J,Zhong Z,Subramaniam S,Raghunandan S,Duran A,Linares JF,Reina-Campos M,Umemura S,Valasek MA,Seki E,Yamaguchi K,Koike K,Itoh Y,Diaz-Meco MT,Moscat J,K

    更新日期：2016-06-13 00:00:00

  • Defining UHRF1 Domains that Support Maintenance of Human Colon Cancer DNA Methylation and Oncogenic Properties.

    abstract：:UHRF1 facilitates the establishment and maintenance of DNA methylation patterns in mammalian cells. The establishment domains are defined, including E3 ligase function, but the maintenance domains are poorly characterized. Here, we demonstrate that UHRF1 histone- and hemimethylated DNA binding functions, but not E3 li...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2019.03.003

    authors： Kong X,Chen J,Xie W,Brown SM,Cai Y,Wu K,Fan D,Nie Y,Yegnasubramanian S,Tiedemann RL,Tao Y,Chiu Yen RW,Topper MJ,Zahnow CA,Easwaran H,Rothbart SB,Xia L,Baylin SB

    更新日期：2019-04-15 00:00:00

  • Dynamic ROS Control by TIGAR Regulates the Initiation and Progression of Pancreatic Cancer.

    abstract：:The TIGAR protein has antioxidant activity that supports intestinal tissue repair and adenoma development. Using a pancreatic ductal adenocarcinoma (PDAC) model, we show that reactive oxygen species (ROS) regulation by TIGAR supports premalignant tumor initiation while restricting metastasis. Increased ROS in PDAC cel...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2019.12.012

    authors： Cheung EC,DeNicola GM,Nixon C,Blyth K,Labuschagne CF,Tuveson DA,Vousden KH

    更新日期：2020-02-10 00:00:00

  • Neutrophils Oppose Uterine Epithelial Carcinogenesis via Debridement of Hypoxic Tumor Cells.

    abstract：:Polymorphonuclear neutrophils (PMNs) are largely considered to foster cancer development despite wielding an arsenal of cytotoxic agents. Using a mouse model of PTEN-deficient uterine cancer, we describe a surprising inhibitory role for PMNs in epithelial carcinogenesis. By inducing tumor cell detachment from the base...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2015.11.005

    authors： Blaisdell A,Crequer A,Columbus D,Daikoku T,Mittal K,Dey SK,Erlebacher A

    更新日期：2015-12-14 00:00:00

  • ADORA1 Inhibition Promotes Tumor Immune Evasion by Regulating the ATF3-PD-L1 Axis.

    abstract：:Here, we show that tumor ADORA1 deletion suppresses cell growth in human melanoma cell lines in vitro and tumor development in vivo in immune-deficient xenografts. However, this deletion induces the upregulation of PD-L1 levels, which inactivates cocultured T cells in vitro, compromises anti-tumor immunity in vivo, an...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2020.02.006

    authors： Liu H,Kuang X,Zhang Y,Ye Y,Li J,Liang L,Xie Z,Weng L,Guo J,Li H,Ma F,Chen X,Zhao S,Su J,Yang N,Fang F,Xie Y,Tao J,Zhang J,Chen M,Peng C,Sun L,Zhang X,Liu J,Han L,Xu X,Hung MC,Chen X

    更新日期：2020-03-16 00:00:00

  • Undifferentiated Sarcomas Develop through Distinct Evolutionary Pathways.

    abstract：:Undifferentiated sarcomas (USARCs) of adults are diverse, rare, and aggressive soft tissue cancers. Recent sequencing efforts have confirmed that USARCs exhibit one of the highest burdens of structural aberrations across human cancer. Here, we sought to unravel the molecular basis of the structural complexity in USARC...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2019.02.002

    authors： Steele CD,Tarabichi M,Oukrif D,Webster AP,Ye H,Fittall M,Lombard P,Martincorena I,Tarpey PS,Collord G,Haase K,Strauss SJ,Berisha F,Vaikkinen H,Dhami P,Jansen M,Behjati S,Amary MF,Tirabosco R,Feber A,Campbell PJ,

    更新日期：2019-03-18 00:00:00

  • Dynein light chain 1, a p21-activated kinase 1-interacting substrate, promotes cancerous phenotypes.

    abstract：:We identified dynein light chain 1 (DLC1) as a physiologic substrate of p21-activated kinase 1 (Pak1). Pak1-DLC1 interaction plays an essential role in cell survival, which depends on Pak1's phosphorylation of DLC1 on Ser88. Pak1 associates with the complex of DLC1 and BimL, a proapoptotic BH3-only protein, and phosph...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2004.05.022

    authors： Vadlamudi RK,Bagheri-Yarmand R,Yang Z,Balasenthil S,Nguyen D,Sahin AA,den Hollander P,Kumar R

    更新日期：2004-06-01 00:00:00

  • What has senescence got to do with cancer?

    abstract：:Cancer therapeutics are primarily thought to work by inducing apoptosis in tumor cells. However, various tumor suppressors and oncogenes have been shown to regulate senescence in normal cells, and senescence bypass appears to be an important step in the development of cancer. Cellular senescence limits the replicative...

    journal_title：Cancer cell

    pub_type： 杂志文章,评审

    doi：10.1016/j.ccr.2005.05.025

    authors： Dimri GP

    更新日期：2005-06-01 00:00:00

  • Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression.

    abstract：:Controversy over the role of antioxidants in cancer has persisted for decades. Here, we demonstrate that synthesis of the antioxidant glutathione (GSH), driven by GCLM, is required for cancer initiation. Genetic loss of Gclm prevents a tumor's ability to drive malignant transformation. Intriguingly, these findings can...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2014.11.019

    authors： Harris IS,Treloar AE,Inoue S,Sasaki M,Gorrini C,Lee KC,Yung KY,Brenner D,Knobbe-Thomsen CB,Cox MA,Elia A,Berger T,Cescon DW,Adeoye A,Brüstle A,Molyneux SD,Mason JM,Li WY,Yamamoto K,Wakeham A,Berman HK,Khokha R,

    更新日期：2015-02-09 00:00:00

  • Long Noncoding RNAs in Cancer Pathways.

    abstract：:Genome-wide cancer mutation analyses are revealing an extensive landscape of functional mutations within the noncoding genome, with profound effects on the expression of long noncoding RNAs (lncRNAs). While the exquisite regulation of lncRNA transcription can provide signals of malignant transformation, we now underst...

    journal_title：Cancer cell

    pub_type： 杂志文章,评审

    doi：10.1016/j.ccell.2016.03.010

    authors： Schmitt AM,Chang HY

    更新日期：2016-04-11 00:00:00

  • miR-30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis.

    abstract：:To metastasize, a tumor cell must acquire abilities such as the capacity to colonize new tissue and evade immune surveillance. Recent evidence suggests that microRNAs can promote the evolution of malignant behaviors by regulating multiple targets. We performed a microRNA analysis of human melanoma, a highly invasive c...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2011.05.027

    authors： Gaziel-Sovran A,Segura MF,Di Micco R,Collins MK,Hanniford D,Vega-Saenz de Miera E,Rakus JF,Dankert JF,Shang S,Kerbel RS,Bhardwaj N,Shao Y,Darvishian F,Zavadil J,Erlebacher A,Mahal LK,Osman I,Hernando E

    更新日期：2011-07-12 00:00:00

  • Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia.

    abstract：:To identify FDA-approved agents targeting leukemic cells, we performed a chemical screen on two human leukemic cell lines and identified the antimicrobial tigecycline. A genome-wide screen in yeast identified mitochondrial translation inhibition as the mechanism of tigecycline-mediated lethality. Tigecycline selective...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2011.10.015

    authors： Skrtić M,Sriskanthadevan S,Jhas B,Gebbia M,Wang X,Wang Z,Hurren R,Jitkova Y,Gronda M,Maclean N,Lai CK,Eberhard Y,Bartoszko J,Spagnuolo P,Rutledge AC,Datti A,Ketela T,Moffat J,Robinson BH,Cameron JH,Wrana J,Eaves

    更新日期：2011-11-15 00:00:00